Study identifier:D1447C00134
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Multicentre, double-blind, randomised, parallel group, placebo controlled, phase 3 study of the efficacy & safety of quetiapine fumarate & paroxetine as monotherapy in adult patients with bipolar depression for 8 weeks & quetiapine in continuation (Abbreviated)
Bipolar Disorder
Phase 3
No
quetiapine fumarate (Seroquel), paroxetine
All
676
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
Location
Location
Little Rock, Arkansas, United States
Location
Phoenix, AZ, United States
Location
National City, CA, United States
Location
San Diego, CA, United States
Location
Maitland, FL, United States
Location
Atlanta, GA, United States
Location
Smyrna, GA, United States
Location
Oak Brook, IL, United States
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.